Clinicopathological Features and Survival of Young Turkish Patients with Testicular Germ Cell Tumors
| Autor: | Bülent Karagöz, Levent Emirzeoglu, Alpaslan Ozgun, Oğuz Bilgi, Tolga Tuncel, Serkan Celik |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Lung Neoplasms Turkey Epidemiology medicine.medical_treatment Testicular Germ Cell Tumor Malignancy Retroperitoneal lymph node dissection Testicular Neoplasms Internal medicine medicine Humans Stage (cooking) Survival rate Survival analysis Neoplasm Staging Retrospective Studies business.industry Liver Neoplasms Public Health Environmental and Occupational Health Seminoma Middle Aged Neoplasms Germ Cell and Embryonal Prognosis medicine.disease Combined Modality Therapy Surgery Survival Rate Lymphatic Metastasis Germ cell tumors Neoplasm Recurrence Local business Follow-Up Studies |
| Zdroj: | Asian Pacific Journal of Cancer Prevention. 14:6889-6892 |
| ISSN: | 1513-7368 |
| Popis: | Background: Testicular germ cell tumors (TGCTs) are a relatively common malignancy in young men. The aim of this study was to investigate the clinicopathological features and survival of young Turkish patients with TGCT. Materials and Methods: In this retrospective study, the clinical and pathological characteristics of young Turkish patients with TGCT who were monitored by the Department of Medical Oncology of a military hospital between 2008 and 2013 were investigated. Overall survival data were analyzed. Results: Ninety-six patients were included in the study. The mean age was 26.4 years. Among the patients, 17.7% had seminoma and 43.8% had mixed non-seminomatous germ cell tumors. Some 46.9% were Stage I, 30.2% were Stage II, and 22.9 were Stage III. Of the patients, 83.3% received chemotherapy, 25% underwent retroperitoneal lymph node dissection (RPLND), 3.1% received radiotherapy, and 12.5% were followed-up without treatment. In addition, 18.8% of the patients were administered salvage chemotherapy due to relapse or progression. The 5-year overall survival rate was 90.2% for all patients. The 2-year overall survival rate was 100% for Stage I patients, 94% for Stage II patients, and 70.2% for Stage III patients. The difference between the survival curves of stages was statistically significant (p=0.029). Conclusions: In young Turkish patients with TGCT, good results were obtained with appropriate treatment, most receiving chemotherapy. The prognosis of the disease was good even in the advanced stage. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|